Stage III NSCLC

Osimertinib is approved by the USFDA for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy

On September 25, 2024, the Food and Drug Administration sanctioned osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for adult patients with locally advanced, unresectable (stage III) non-small ce...
stage-iii-nsclc

Scan the code

Tag: Stage III NSCLC

Home / Stage III NSCLC

Categories

Osimertinib is approved by the USFDA for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy

Information

Treatment

United States

Romania

India (Hyderabad)

Cambodia

China (Shanghai)

China (Beijing)

Hong Kong